AI summary by TwinMind

The Promise and Peril of Fast-Tracking the Coronavirus Vaccine | WSJ

The Wall Street Journal

8m 15s

Vaccine Development Timeline Crisis

  • Coronavirus crisis forcing breakneck pace vaccine development
  • Economies cannot reopen safely/permanently without effective vaccine
  • Traditional vaccine development: average 10 years (2013 study)
  • COVID-19 vaccine target: 12-18 months to market
  • Emergency use authorization possible before end of year

Factors Enabling Accelerated Development

  • Prior knowledge of coronaviruses (SARS, MERS)
  • Improvements in viral genome sequencing
  • Advancements in bioengineering technologies
  • Unprecedented government support and funding
  • Shortened testing timeline through parallel processing

Traditional vs. Accelerated Testing Process

  • Traditional sequence: cells → animals (mice → monkeys) → challenge studies → human trials
  • Each phase requires safety/effectiveness proof before advancing
  • Challenge studies: vaccinate animal, intentionally expose to virus
  • Three stages human trials, each testing more people
  • FDA approval required for each stage
  • Current approach: parallel testing instead of sequential
    • Not skipping steps, doing simultaneously
    • Costs significantly more, requires more work

Current Development Status

  • Novel coronavirus discovered/sequenced <6 months ago
  • Phase 1 human trials already started: Inovio, Pfizer
  • Moderna started Phase 2
  • Others preparing Phase 2 before Phase 1 completion
  • Phase 1 trials typically run 1 year, but not waiting full period
  • Expediting due to COVID-19 devastation concerns

Vaccine Mechanism and Target

  • Vaccines trick body into thinking virus infiltrated
  • Immune system produces antibodies/defenses
  • Target: spike protein (virus uses to enter cells)
  • SARS/MERS showed spike protein = major neutralizing antibody target
  • Neutralizing antibodies essential to fight infection

Herd Immunity Concept

  • Pandemic ends when sufficient population immunity achieved
  • Immunity sources: natural infection or vaccination
  • Vaccination = "gentler path" than mass infection
  • Largest, most collaborative vaccine development effort in scientists' lifetimes

Four Main Vaccine Strategies

Weakened/Inactivated Virus Vaccines

  • Most common type (annual flu shot)
  • Most experience with this approach
  • Costly, time-consuming mass production
  • Not preferred approach for COVID-19

Protein-Based Vaccines

  • Carry key virus parts (spike protein) into body
  • Developers: Sanofi, GlaxoSmithKline, dozens others
  • More diverse proteins with various shapes/characteristics
  • Require more development work

Viral Vector Vaccines

  • Use inactivated virus stuffed with spike protein genetic code
  • Cells produce viral proteins, immune system recognizes
  • Johnson & Johnson developing this type
  • Uses adenovirus (common cold virus, replication incompetent)

Genetic Code Vaccines

  • Contain spike protein instructions
  • Developers: Inovio, Pfizer, Moderna
  • Never approved for humans before
  • Generating excitement due to speed in development/manufacturing

Manufacturing and Safety Concerns

  • Pfizer running multiple candidates (US, Germany)
  • Ramping manufacturing capacity before knowing effectiveness
  • Key requirements: safety, effectiveness, consistency
  • Manufacturing changes can introduce unforeseen safety issues
  • Historical example: discontinued polio vaccine
  • Vaccines given to healthy people, must ensure no organ function impact

Production and Distribution Challenges

  • Goal: 1 billion doses by end 2021
  • Other companies committing hundreds of millions/billions
  • Still insufficient for global population
  • Unknown protection durability: 6 months to 2+ years
  • If short duration, frequent boosting required

Human Behavior Hurdle

  • Final, most important obstacle
  • Vaccine acceptance crucial for success
  • 50% rejection rate would defeat purpose
  • Major problem in US population

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome